Spectrum Dynamics Medical’s Post

🚀 Edgewise Therapeutics' Cardiomyopathy Data Shows Blockbuster Potential 💥💊 Edgewise Therapeutics has unveiled impressive early results for EDG-7500, a novel treatment for obstructive hypertrophic cardiomyopathy (oHCM) 💓. Following the data release, the company’s share price surged by two-thirds 📈, now at $29.50, with analysts projecting peak sales of $2 billion 💰 by the mid-2030s, pending approval. The Phase I trial showed a clean safety profile 🧬, and the Phase II CIRRUS-HCM trial demonstrated promising heart function improvements 🫀. EDG-7500 could be a game-changer 🎯 for those with oHCM, and we’re eager to see what’s next. #Cardiomyopathy #Biotech #Pharma #Citeline #oHCM #clinicaltrials #Cardiology

Discounts for the Neuromodulation Summit 2024 expire this Friday! 📢 Check out the full event guide now: https://ter.li/rw1ht3 This exclusive conference is industry’s must-attend meeting to join the community of 80+ experts in neuromodulation to share crucial insights into: ✅ How the CDRH is accelerating patient access to innovation ✅ How to overcome regulatory and clinical challenges to receive funding ✅ How the adoption of invasive and non-invasive devices differs ✅ How to choose which submission type is the best first step Joined by the likes of FDA, LivaNova, Axonics, Inc., Cognito Therapeutics, Inc., Neuspera Medical Inc., ClearPoint Neuro, Inc. and many more - this is not one to miss! Save up to $400 on your pass and join them in Boston this June: https://ter.li/wummg3

🚨 Capricor Therapeutics to File BLA for Duchenne Muscular Dystrophy (DMD) Cardiomyopathy Treatment 🚨 Capricor Therapeutics, a leader in innovative cell and exosome-based therapies, announced plans to file a Biologics License Application (BLA) for *deramiocel* following discussions with the FDA. The filing will focus on treating DMD cardiomyopathy using existing cardiac data. Key updates: 📅 BLA Filing Timeline: Filing begins October 2024, with full submission anticipated by year-end. 📊 Data Sources:  Application will leverage Phase 2 HOPE-2 and HOPE-2 OLE trial data, alongside natural history data from Vanderbilt University and Cincinnati Children’s Hospital. 🔬 Next Steps for Skeletal Muscle Myopathy Treatment: Capricor plans to combine cohorts from the Phase 3 HOPE-3 trial for post-approval study, deferring the unblinding of Cohort A. A major milestone in the fight against DMD – stay tuned for more updates! #biotech #FDA #capricor #duchennemusculardystrophy #healthcareinnovation Karan Chechi | Alwin Samuel | Shaurya Singh | TechSci Research

Beacon Therapeutics presented 12-month data from its Phase II SKYLINE trial of its lead asset, AGTC-501, in XLRP at the Annual Macula Society Meeting, demonstrating encouraging efficacy and safety.   The presentation highlighted encouraging efficacy shown by improvements in retinal sensitivity, the primary endpoint for the trial, with a 63% response rate in the higher dose cohort. Beacon expects to announce longer term 24-month data from the trial in H2 CY2024.   Read the full announcement here: https://lnkd.in/d4Qfpq6d   #ophthalmology #blindness

Axoltis Pharma receives authorization to launch SEALS - phase II clinical trial for ALS patients with drug candidate NX210c ☑️ Phase II trial will assess efficacy and tolerability of NX210c in Amyotrophic Lateral Sclerosis (ALS) patients ☑️ 80 patients due to be enrolled with first results expected in early 2026 ☑️ NX210c drug candidate allows for promising approach to repairing Blood Brain Barrier (BBB) which is impaired in neurodegenerative diseases such as ALS https://lnkd.in/eYiaFfs5

Introducing, Joshua Reeder, PhD student, pharmaceutical sciences and experimental therapeutics. "My goal is to find the right redosing frequency for patients undergoing prolonged surgeries, improving patient safety and preventing surgical site infections." Reeder is featured in the University of Iowa 2024 “Dare to Discover” campaign highlighting outstanding student researchers. #DiscoverUI #UIowaPharmSci #pharmhawks #uipharmacyleads

Halia Therapeutics, Inc.'s and Biolexis Therapeutics, Inc.'s partnership have identified a novel brain-penetrant small molecule candidate targeting NLRP3-driven neuroinflammation by leveraging Biolexis’ MolecuLern™ AI-enabled approach. This milestone represents a significant advancement in treatments for neuroinflammatory disorders, including Parkinson’s. #HaliaTherapeutics #BiolexisTherapeutics #BioUtah #UtahLifeSciences https://ow.ly/Jqow50SSyf2

#ACC24 Spotlight: Data from the IMPROVE-HCM trial, presented by Martin S. Maron, MD, of Lahey Hospital & Medical Center, offer hope for patients with nonobstructive HCM, as results of the phase 2 trial suggest use of ninerafaxstat, a cardiac mitotrope from Imbria Pharmaceuticals, was well-tolerated and improved exercise capacity among patients with nonobstructive hypertrophic cardiomyopathy. Check out our coverage here: https://lnkd.in/eJfG2y6q #Cardiomyopathy #Cardiology

Isn't it time that your office offered Virtual Reality to your Patients? Isn't it time that your Dentist offered Virtual Reality to help reduce and even eliminate completely your anxiety and pain? Contact me to find out how!

 In recognition of National Glaucoma Awareness Month, we would like to continue to spotlight our portfolio companies working towards better treatments of Glaucoma. At OIS XIII, CEO David Esposito discussed ONL’s lead compound, ONL1204, and its promise across various eye indications. In geographic atrophy (GA), a single injection demonstrated a 42% slowing of lesion growth over six months. In open-angle glaucoma, ONL1204 indicated structural and functional improvement in under 12 months. ONL Therapeutics aims to provide IOP-independent neuroprotection for glaucoma. They plan to report topline results for retinal detachment in April-May, progress to a registrational study for GA in 2024, and explore neuroenhancement in glaucoma with a potential Phase 2 study in 2025. Watch the full video below: #glaucomaawareness #glaucomaawarenessmonth #investintheeye #ophthalmology https://lnkd.in/eHziCgaV